KRAS-Mutant Non-Small Cell Lung Cancer: From Biology to Therapy
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are found in approximately 20 –25% of lung adenocarcinomas in Western countries [1–3] and in approximately 10–15% of cases in Asia [4,5]. Considered globally, KRAS-mutant tumours constitute the most frequent potentially targetable molecular subtype of non-small-cell lung cancer (NSCLC) [6]. As is the case with the vast maj ority of potentially actionable genetic alterations in NSCLC, KRAS mutations are almost exclusively detected in lung adenocarcinomas and are rarely found in squamous-cell cancers [7,8].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Irene Ferrer, Jon Zugazagoitia, Stephan Herbertz, William John, Luis Paz-Ares, Gerald Schmid-Bindert Tags: Review Source Type: research
More News: Adenocarcinoma | Biology | Cancer | Cancer & Oncology | Genetics | Lung Cancer | Molecular Biology | Non-Small Cell Lung Cancer | Sarcomas | Squamous Cell Carcinoma